الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 74 |  |  |
| | | from | 74 | | |
Abstract
This study is A prospective multi-center Cohort study was conducted to Measure the relation between COVID-19 infection and relapse rate in comparison with average annual relapse rate (ARR) in MS patients assessment of infection severity according to line of disease modifying treatment(DMT) in different Patients determining the effect of COVID19 infection on EDSS
Demographic and clinical data were obtained from patients and medical records including date of onset and the nature of the first MS related presenting symptoms, date of diagnosis of MS, date of advice to start a (DMT), current DMT, total number of relapses during the course of disease, number of relapses annually, the EDSS scores were obtained from the patients records throughout their illness namely the EDSS scores before and after six month, the MRI scans of the patients were reviewed before and after six month from starting the current disease for the number of T2 lesions, T1 hypointensity, and the CT chest of the patient during COVID 19 infection.
79.3% of the selected patients are female Most of the patients were not smokers nor pregnant, and there were very low percentage of patients with other risk factors
Most of the patients were presented with fever, fatigue, sore throat, dry cough, anosmia and loss of taste as symptoms of COVID infection Only 2% of the patients in the study were admitted to ICU, and only 1.4% of them were mechanically ventilated survival rate of COVID in studied patients is 99.3% The mean of duration of recovery from COVID was around 10 days
Summary
51
that there was no significant increase in number of relapses in the 6 months follow up after COVID yet the number of patients experiencing relapses is decreasing there is no significant relation between line of treatment and COVID severity and that there is no significant relation between the age of MS patient and COVID severity.
And that male MS patients has higher possibility of having more severe COVID than female MS patients.
Also shows that the higher the EDSS of the patients the more severe COVID infection is; and that patients with relapses in the last six months before COVID shows more severe COVID infection than patients with no relapses and also there is high significant increase in number of studied MS patients that had increase in their EDSS in the 6 months follow up; yet this is only marginal increase.